HUMAN ANTI EGF RECEPTOR (CETUXIMAB BIOSIMILAR)

Human Anti-EGF R Antibody, clone C225 is a research grade biosimilar of the monoclonal antibody drug cetuximab. It is a recombinant human IgG1 kappa antibody with variable regions from the therapeutic antibody cetuximab. Human Anti-EGF R Antibody is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-cetuximab antibodies, for example HCA220 and HCA221P. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-cetuximab antibody in IgG1 format as reference standard, for example HCA221. Cetuximab (Erbitux) is a chimeric monoclonal antibody drug (IgG1/kappa) approved for treatment of KRAS wild-type metastatic colorectal cancers and squamous cell carcinoma of the head and neck. This therapeutic antibody is directed against EGFR and inhibits tumor cell proliferation by blocking the interaction of epidermal growth factor (EGF) with its receptor. This product is NOT FOR THERAPEUTIC USE.View a summary of supporting anti-cetuximab antibody products

• Clonality: Monoclonal
• Host: Human
• Reactivity: Human
• Isotype: IgG1

• Quantity: 0.2 mg
• Storage: +4ºC, -20ºC if preferred
• Buffer: Phosphate buffered saline, 0.02% Proclin 300

• ELISA (ELISA)